

VBC Release Highlights

May 2022

Practice Insights is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS).

MIPS Quality Measures Dashboard

The MIPS Quality Measures Dashboard has been updated to reflect 2022 specification changes for:

| Measure | Update | Practice Impact |
|--|---|--|
| MIPS 144: Pain Care Plan | The following ICD-10 Codes were added as an applicable Denominator credit code: C56.3, C79.63, and C84.7A | Practices will not notice a shift in their scores. |
| MIPS 453: Chemotherapy in the Last 14 Days of Life | The following ICD-10 Codes were added as an applicable Denominator credit code: C56.3, C79.63, and C84.7A | Practices will not notice a shift in their scores. |

Status of Dashboard Updates for 2022

CMS releases updates to the quality measure specifications annually for the MIPS program and bi-annually for the OCM program. These measure specifications have been reviewed and Practice Insights is currently working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2022 requirements. The measures listed below either have no 2022 update required or have been updated.

| Measure | Description |
|--|---|
| MIPS Quality Measures Dashboard | |
| #047 | Advance Care Plan |
| #110 | Preventive Care and Screening: Influenza Immunization |
| #128 | Body Mass Index (BMI) Screening and Follow-Up Plan |
| #130 | Current Medications Documentation |
| #134 | Depression Screening |
| #143 | Pain Intensity Quantified |
| #144 | Pain Care Plan |
| #226 | Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention |
| #374 | Closing the Referral Loop |
| #451 | RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy |
| #453 | Proportion Receiving Chemotherapy in the Last 14 Days of Life (Inverse Measure) |
| PIMSH#1 | Advance Care Planning in Metastatic Cancer |
| PIMSH#2 | Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure) |
| PIMSH#4 | Patient-Reported Pain Improvement |
| PIMSH#9 | Supportive Care Drug Utilization in the Last 14 Days |

| Measure | Description |
|---|--|
| | of Life (Inverse Measure) |
| PIMSH#10 | Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti CD20 Targeting Drugs |
| OCM Performance Measures Dashboard 1H 2022 | |
| OCM 4A | Pain Intensity Quantified |
| OCM 4B | Plan of Care for Pain |
| OCM5 | Depression Screening |